News & Events
PAS, An Interview with Lynda Sutton
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers.
Cancer Advances, Inc. Announces Abstract and Poster Presentation at ASCO GI – Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer
DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a virtual presentation of its poster at the American Society of Clinical Oncology’s (ASCO) Gastrointestinal Cancers Symposium being held from January 20-22, 2022, at the Moscone West Building in San Francisco, CA.
Cancer Advances, Inc. Announces Publication, “Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer” in Frontiers in Oncology
DURHAM, N.C., Dec. 06, 2021 — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in Frontiers in Oncology, section Gastrointestinal Cancers: Gastric & Esophageal Cancers.
The gastrointestinal peptide gastrin has been shown to stimulate growth of gastric cancer through the cholecystokinin-B receptor (CCK-BR), a receptor that is expressed in at least 56.6% of human gastric cancers. The researchers evaluated the effects of PAS (Polyclonal Antibody Stimulator), a Phase 3 ready cancer vaccine that induces antibodies to gastrin, alone or in combination with a Programed Death-1 antibody (PD-1 Ab) in immune competent mice bearing YTN-16 gastric tumors.
Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model
The incidence of pancreatic cancer is increasing significantly and will soon become the second leading cause of cancer-related deaths in the United States. We have previously
shown that the gastrointestinal peptide gastrin, which is only expressed in the fetal pancreas and not in the adult pancreas, is activated during pancreatic carcinogenesis
where it stimulates growth in an autocrine fashion. In this investigation, we used transgenic LSL-KrasG12D/þ; P48-Cre mice that develop precancerous pancreatic intraepithelial neoplasia (PanIN) lesions and pancreatic cancer over time. Starting at 3 months of age, mice were either left untreated (control) or were treated with a gastrin-targeted vaccine,
polyclonal antibody stimulator (PAS 250 mg) followed by a monthly booster until the mice reached 8 months of age when pancreata were excised, and analyzed by histology for PanIN grade in a blinded fashion. Highgrade PanIN-3 lesions were significantly less in PAStreated mice (P ¼ 0.0077), and cancers developed in 33% of the control mice but only in 10% of the PAStreated
mice. Compared with the control mice, fibrosis was reduced by >50%, arginase positive M2 macrophages were reduced by 74%, and CD8þ T cells were increased
by 73% in the pancreas extracellular matrix in PAS-treated mice.
Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that its abstract entitled, “Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse...
Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually...
November 11, 2019 – Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology
• Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. • PAS vaccine decreased metastasis by decreasing key pathway proteins involved in...
November 11, 2019 – Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy
• Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy. • Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune...
© 2020 Cancer Advances, Inc. All rights reserved.